Lucida Clinical Trials
Welcome,         Profile    Billing    Logout  
 5 Trials 
71 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Patel, Anand
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Active, not recruiting
4
262
US
Pegloticase, Methotrexate
Amgen
Gout
09/25
05/26
NCT04638647 / 2020-004284-98: Secukinumab Open Label Roll-over Extension Protocol

Recruiting
4
715
Europe, US, RoW
Secukinumab s.c. injection
Novartis Pharmaceuticals
Autoimmunity, Inflammation
01/30
04/30
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
MSB-DR004, NCT06325566: Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

Recruiting
3
300
US
Rexlemestrocel-L + HA mixture, Saline
Mesoblast, Ltd.
Degenerative Disc Disease
10/26
10/27
NCT05758415: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Terminated
3
60
Europe, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
10/24
12/24
NCT06917404: A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

Recruiting
3
466
US, RoW
Pentosan Polysulfate Sodium twice weekly, Placebo
Paradigm Biopharmaceuticals Ltd.
Osteoarthritis, Knee
07/27
07/27
TRIUMPH-7, NCT07035093: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Recruiting
3
586
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Chronic Low Back Pain (CLBP)
09/27
09/27
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
2/3
351
US
Buntanetap/Posiphen, Posiphen Tartrate, Placebo
Annovis Bio Inc.
Alzheimer Disease
02/24
02/24
NCT04809376: Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Active, not recruiting
2/3
602
US, RoW
Pentosan Polysulfate Sodium twice weekly, PPS twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Placebo, Pentosan Polysulfate Sodium Fixed Dose, Fixed Dose, Pentosan Polysulfate Sodium once weekly, PPS once weekly
Paradigm Biopharmaceuticals USA (INC)
Osteoarthritis, Knee
10/24
01/25
SAP-001-202, NCT05690204: Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

Active, not recruiting
2
87
US
SAP-001, Xanthine Oxidase Inhibitor, Colchicine
Shanton Pharma Pte. Ltd.
Gout
01/25
02/25
Saol 1010-01, NCT05470608: Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain

Active, not recruiting
2
132
US
SL-1002, Placebo
Saol Therapeutics Inc
Osteoarthritis, Knee Pain
01/24
01/24
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
NCT06293365: Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Recruiting
2
140
Europe, Canada, US, RoW
VAY736 1ml PFS, Ianalumab, VAY736 2 ml PFS, VAY736 2ml AI
Novartis Pharmaceuticals
Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
07/25
02/29
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

Recruiting
2
450
Europe, Canada, Japan, US, RoW
LY3848575, Placebo
Eli Lilly and Company
Neuropathic Pain, Distal Sensory Polyneuropathy
06/26
09/26
NCT04886258 / 2020-006104-17: Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

Completed
2
115
Europe, US, RoW
DFV890, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Symptomatic Knee Osteoarthritis
12/24
12/24
NCT06884865: A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee

Recruiting
2
135
US
Enekinragene Inzadenovec (PCRX-201), Placebo
Pacira Pharmaceuticals, Inc
Osteoarthritis (OA) of the Knee
03/27
03/32
MyeloMATCH, NCT06577441: Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A Treatment Trial)

Recruiting
2
54
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Enasidenib, AG 221, AG-221, AG221, CC-90007 Free Base
National Cancer Institute (NCI)
Myelodysplastic Syndrome
03/27
03/27
NCT06661915: A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Recruiting
2
62
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Iadademstat, ORY 1001, ORY-1001, RG 6016, RG6016, RO 7051790, RO7051790, trans-N1-((1R,2S)-2-Phenylcyclopropyl)-1,4-cyclohexanediamine
National Cancer Institute (NCI)
Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Not Otherwise Specified, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
12/27
12/27
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain

Terminated
2
209
US
RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo
Biogen
Diabetic Peripheral Neuropathic Pain
11/24
11/24
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

Recruiting
2
10000
US
LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo
Eli Lilly and Company
Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
04/27
04/27
KB-LANRA- 1001, NCT05028751 / 2022-001279-15: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Terminated
1/2
24
Europe, US
Lanraplenib, LANRA, Gilteritinib, XOSPATA®
Kronos Bio, Kronos Bio, Inc.
Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
04/24
04/24
NCT03709758: Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

Recruiting
1
64
US
Venetoclax, Venclexta, Daunorubicin, Cerubidine, Cytarabine, Cytosar-U
Dana-Farber Cancer Institute, AbbVie, Genentech, Inc.
Acute Myeloid Leukemia
12/25
06/26
NCT06291987: Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

Recruiting
1
18
US
Ivosidenib, TIBSOVO, Ruxolitinib, Jakafi
University of Chicago
Myeloproliferative Neoplasms
05/26
05/26
NCT06730594: A Study to Assess the Effect of the Bio-K+ Probiotic Capsules (VL-BK-02) in Adults With Functional Constipation

Recruiting
N/A
126
RoW
VL-BK-02 (25 billion CFU/Capsule), Placebo (Microcrystalline Cellulose - 375 mg/capsule)
Vedic Lifesciences Pvt. Ltd.
Functional Constipation
12/25
12/25
Fischer, Monika
COMPASS-CD, NCT04809363: A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Active, not recruiting
4
200
US
CDPATH™, PROSPECT, Blood Draw
Takeda
Crohn's Disease
10/25
06/26
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
NCT03617445: Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

Terminated
2
3
US
FMT oral capsule, MTP-101-C, Oral Vancomycin, vancomycin, FMT oral placebo, Placebo MTP-101-C, Oral Vancomycin placebo, placebo
University of Wisconsin, Madison, National Institute of Allergy and Infectious Diseases (NIAID)
Clostridium Difficile Infection Recurrence
06/23
06/23
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Completed
2
153
Europe, Canada, US
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Takeda
Celiac Disease
11/24
11/24
VNS, NCT05165108: Non-invasive Vagus Nerve Stimulation in the Treatment of Crohn's Disease - A Pilot Study

Terminated
N/A
4
US
Vagal Nerve Stimulator, GammaCore nVNS
Indiana University, ElectroCore INC
Crohn Disease
08/22
08/22
NCT03325855: Fecal Microbiota Transplant National Registry

Recruiting
N/A
4000
Canada, US
None - Observational, Observational
American Gastroenterological Association, OpenBiome, University of California, San Diego, Commure, University of Pennsylvania, University of Minnesota, Loyola University Chicago
Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
08/27
08/27
Sutton, David
DREAM-T2D, NCT04854512 / 2020-000763-23: Investigational Study of Delayed Release Metformin

Suspended
3
675
Europe, Canada, US, RoW
Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Anji Pharma
Diabetes Mellitus, Type 2
12/23
06/24
NCT06952530: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

Recruiting
3
487
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Hypertension
09/27
09/27
NCT06948435: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Recruiting
3
487
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Hypertension, Overweight or Obesity
09/27
09/27
NCT06948422: A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

Recruiting
3
974
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Hypertension
09/27
09/27
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

Completed
N/A
244
US
MiniMed 780G System
Medtronic Diabetes, Eli Lilly and Company
Type 1 Diabetes
01/24
01/24
NCT05238142: In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes

Completed
N/A
574
US
MiniMed™ 780G Insulin Pump system
Medtronic Diabetes
Type 2 Diabetes Treated With Insulin
01/25
01/25
Prier, Kevin T
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Active, not recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
08/26
01/27
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Completed
3
730
Europe, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar
Eli Lilly and Company, Eli Lilly and Company
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
02/24
02/24
SURPASS-T1D-1, NCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Recruiting
3
905
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 1 Diabetes, Obesity, Overweight
05/27
05/27
NCT06047548: A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
400
US
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Overweight, Obesity
05/26
05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

Recruiting
2
10000
US
LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo
Eli Lilly and Company
Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
04/27
04/27
Fitch, Angela Kay
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1217
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
09/26
11/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
263
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
05/25
09/25
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
275
US
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT06124807: A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Completed
2
179
US
LY3305677, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
01/25
07/25
NCT07030868: A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
150
US, RoW
LY6249492, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
09/26
11/26
NCT06467604: CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users

Active, not recruiting
N/A
7
US
Surveys, FCI-II, 3 day Food Diary, Hunger VAS, BED-7, HFSS 2-item food insecurity survey, MESA Neighborhood Healthy Food, Indirect Calorimetry, Body composition, Seca mBCA 554, Anthropometrics, Waist circumference, Height, Weight
University of California, Davis, Knownwell
Obesity
09/25
12/25
Shih, David Joseph
NCT06952530: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

Recruiting
3
487
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Hypertension
09/27
09/27
NCT06948435: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Recruiting
3
487
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Hypertension, Overweight or Obesity
09/27
09/27
NCT06948422: A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

Recruiting
3
974
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Hypertension
09/27
09/27
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1719
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
09/25
09/25
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1217
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
09/26
11/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
263
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
05/25
09/25
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

Recruiting
2
450
Europe, Canada, Japan, US, RoW
LY3848575, Placebo
Eli Lilly and Company
Neuropathic Pain, Distal Sensory Polyneuropathy
06/26
09/26
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
275
US
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT07030868: A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
150
US, RoW
LY6249492, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
09/26
11/26
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

Recruiting
2
10000
US
LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo
Eli Lilly and Company
Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
04/27
04/27
Mbeo, Gilbert
MODEL, NCT05516992: Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine

Active, not recruiting
3
417
US
SB-01 For Injection, Sham Needle
Spine BioPharma, Inc, MCRA
Lumbar Degenerative Disc Disease
03/25
08/25
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

Recruiting
2
450
Europe, Canada, Japan, US, RoW
LY3848575, Placebo
Eli Lilly and Company
Neuropathic Pain, Distal Sensory Polyneuropathy
06/26
09/26
Nedd, Kester
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

Recruiting
2
450
Europe, Canada, Japan, US, RoW
LY3848575, Placebo
Eli Lilly and Company
Neuropathic Pain, Distal Sensory Polyneuropathy
06/26
09/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Patel, Anand
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Active, not recruiting
4
262
US
Pegloticase, Methotrexate
Amgen
Gout
09/25
05/26
NCT04638647 / 2020-004284-98: Secukinumab Open Label Roll-over Extension Protocol

Recruiting
4
715
Europe, US, RoW
Secukinumab s.c. injection
Novartis Pharmaceuticals
Autoimmunity, Inflammation
01/30
04/30
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
MSB-DR004, NCT06325566: Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

Recruiting
3
300
US
Rexlemestrocel-L + HA mixture, Saline
Mesoblast, Ltd.
Degenerative Disc Disease
10/26
10/27
NCT05758415: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Terminated
3
60
Europe, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
10/24
12/24
NCT06917404: A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

Recruiting
3
466
US, RoW
Pentosan Polysulfate Sodium twice weekly, Placebo
Paradigm Biopharmaceuticals Ltd.
Osteoarthritis, Knee
07/27
07/27
TRIUMPH-7, NCT07035093: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Recruiting
3
586
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Chronic Low Back Pain (CLBP)
09/27
09/27
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
2/3
351
US
Buntanetap/Posiphen, Posiphen Tartrate, Placebo
Annovis Bio Inc.
Alzheimer Disease
02/24
02/24
NCT04809376: Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Active, not recruiting
2/3
602
US, RoW
Pentosan Polysulfate Sodium twice weekly, PPS twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Placebo, Pentosan Polysulfate Sodium Fixed Dose, Fixed Dose, Pentosan Polysulfate Sodium once weekly, PPS once weekly
Paradigm Biopharmaceuticals USA (INC)
Osteoarthritis, Knee
10/24
01/25
SAP-001-202, NCT05690204: Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

Active, not recruiting
2
87
US
SAP-001, Xanthine Oxidase Inhibitor, Colchicine
Shanton Pharma Pte. Ltd.
Gout
01/25
02/25
Saol 1010-01, NCT05470608: Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain

Active, not recruiting
2
132
US
SL-1002, Placebo
Saol Therapeutics Inc
Osteoarthritis, Knee Pain
01/24
01/24
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
NCT06293365: Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Recruiting
2
140
Europe, Canada, US, RoW
VAY736 1ml PFS, Ianalumab, VAY736 2 ml PFS, VAY736 2ml AI
Novartis Pharmaceuticals
Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
07/25
02/29
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

Recruiting
2
450
Europe, Canada, Japan, US, RoW
LY3848575, Placebo
Eli Lilly and Company
Neuropathic Pain, Distal Sensory Polyneuropathy
06/26
09/26
NCT04886258 / 2020-006104-17: Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

Completed
2
115
Europe, US, RoW
DFV890, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Symptomatic Knee Osteoarthritis
12/24
12/24
NCT06884865: A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee

Recruiting
2
135
US
Enekinragene Inzadenovec (PCRX-201), Placebo
Pacira Pharmaceuticals, Inc
Osteoarthritis (OA) of the Knee
03/27
03/32
MyeloMATCH, NCT06577441: Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A Treatment Trial)

Recruiting
2
54
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Enasidenib, AG 221, AG-221, AG221, CC-90007 Free Base
National Cancer Institute (NCI)
Myelodysplastic Syndrome
03/27
03/27
NCT06661915: A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Recruiting
2
62
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Iadademstat, ORY 1001, ORY-1001, RG 6016, RG6016, RO 7051790, RO7051790, trans-N1-((1R,2S)-2-Phenylcyclopropyl)-1,4-cyclohexanediamine
National Cancer Institute (NCI)
Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Not Otherwise Specified, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
12/27
12/27
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain

Terminated
2
209
US
RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo
Biogen
Diabetic Peripheral Neuropathic Pain
11/24
11/24
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

Recruiting
2
10000
US
LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo
Eli Lilly and Company
Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
04/27
04/27
KB-LANRA- 1001, NCT05028751 / 2022-001279-15: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Terminated
1/2
24
Europe, US
Lanraplenib, LANRA, Gilteritinib, XOSPATA®
Kronos Bio, Kronos Bio, Inc.
Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
04/24
04/24
NCT03709758: Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

Recruiting
1
64
US
Venetoclax, Venclexta, Daunorubicin, Cerubidine, Cytarabine, Cytosar-U
Dana-Farber Cancer Institute, AbbVie, Genentech, Inc.
Acute Myeloid Leukemia
12/25
06/26
NCT06291987: Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

Recruiting
1
18
US
Ivosidenib, TIBSOVO, Ruxolitinib, Jakafi
University of Chicago
Myeloproliferative Neoplasms
05/26
05/26
NCT06730594: A Study to Assess the Effect of the Bio-K+ Probiotic Capsules (VL-BK-02) in Adults With Functional Constipation

Recruiting
N/A
126
RoW
VL-BK-02 (25 billion CFU/Capsule), Placebo (Microcrystalline Cellulose - 375 mg/capsule)
Vedic Lifesciences Pvt. Ltd.
Functional Constipation
12/25
12/25
Fischer, Monika
COMPASS-CD, NCT04809363: A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Active, not recruiting
4
200
US
CDPATH™, PROSPECT, Blood Draw
Takeda
Crohn's Disease
10/25
06/26
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
NCT03617445: Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

Terminated
2
3
US
FMT oral capsule, MTP-101-C, Oral Vancomycin, vancomycin, FMT oral placebo, Placebo MTP-101-C, Oral Vancomycin placebo, placebo
University of Wisconsin, Madison, National Institute of Allergy and Infectious Diseases (NIAID)
Clostridium Difficile Infection Recurrence
06/23
06/23
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Completed
2
153
Europe, Canada, US
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Takeda
Celiac Disease
11/24
11/24
VNS, NCT05165108: Non-invasive Vagus Nerve Stimulation in the Treatment of Crohn's Disease - A Pilot Study

Terminated
N/A
4
US
Vagal Nerve Stimulator, GammaCore nVNS
Indiana University, ElectroCore INC
Crohn Disease
08/22
08/22
NCT03325855: Fecal Microbiota Transplant National Registry

Recruiting
N/A
4000
Canada, US
None - Observational, Observational
American Gastroenterological Association, OpenBiome, University of California, San Diego, Commure, University of Pennsylvania, University of Minnesota, Loyola University Chicago
Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
08/27
08/27
Sutton, David
DREAM-T2D, NCT04854512 / 2020-000763-23: Investigational Study of Delayed Release Metformin

Suspended
3
675
Europe, Canada, US, RoW
Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Anji Pharma
Diabetes Mellitus, Type 2
12/23
06/24
NCT06952530: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

Recruiting
3
487
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Hypertension
09/27
09/27
NCT06948435: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Recruiting
3
487
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Hypertension, Overweight or Obesity
09/27
09/27
NCT06948422: A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

Recruiting
3
974
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Hypertension
09/27
09/27
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

Completed
N/A
244
US
MiniMed 780G System
Medtronic Diabetes, Eli Lilly and Company
Type 1 Diabetes
01/24
01/24
NCT05238142: In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes

Completed
N/A
574
US
MiniMed™ 780G Insulin Pump system
Medtronic Diabetes
Type 2 Diabetes Treated With Insulin
01/25
01/25
Prier, Kevin T
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Active, not recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
08/26
01/27
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Completed
3
730
Europe, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar
Eli Lilly and Company, Eli Lilly and Company
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
02/24
02/24
SURPASS-T1D-1, NCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Recruiting
3
905
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 1 Diabetes, Obesity, Overweight
05/27
05/27
NCT06047548: A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
400
US
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Overweight, Obesity
05/26
05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

Recruiting
2
10000
US
LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo
Eli Lilly and Company
Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
04/27
04/27
Fitch, Angela Kay
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1217
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
09/26
11/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
263
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
05/25
09/25
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
275
US
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT06124807: A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Completed
2
179
US
LY3305677, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
01/25
07/25
NCT07030868: A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
150
US, RoW
LY6249492, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
09/26
11/26
NCT06467604: CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users

Active, not recruiting
N/A
7
US
Surveys, FCI-II, 3 day Food Diary, Hunger VAS, BED-7, HFSS 2-item food insecurity survey, MESA Neighborhood Healthy Food, Indirect Calorimetry, Body composition, Seca mBCA 554, Anthropometrics, Waist circumference, Height, Weight
University of California, Davis, Knownwell
Obesity
09/25
12/25
Shih, David Joseph
NCT06952530: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

Recruiting
3
487
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Hypertension
09/27
09/27
NCT06948435: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Recruiting
3
487
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Hypertension, Overweight or Obesity
09/27
09/27
NCT06948422: A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

Recruiting
3
974
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Hypertension
09/27
09/27
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1719
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
09/25
09/25
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1217
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
09/26
11/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
263
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
05/25
09/25
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

Recruiting
2
450
Europe, Canada, Japan, US, RoW
LY3848575, Placebo
Eli Lilly and Company
Neuropathic Pain, Distal Sensory Polyneuropathy
06/26
09/26
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
275
US
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT07030868: A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
150
US, RoW
LY6249492, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
09/26
11/26
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

Recruiting
2
10000
US
LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo
Eli Lilly and Company
Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
04/27
04/27
Mbeo, Gilbert
MODEL, NCT05516992: Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine

Active, not recruiting
3
417
US
SB-01 For Injection, Sham Needle
Spine BioPharma, Inc, MCRA
Lumbar Degenerative Disc Disease
03/25
08/25
NCT06709014: A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Recruiting
3
760
US
buntanetap/posiphen, Placebo
Annovis Bio Inc., Prevail Infoworks
Early Alzheimers Disease
12/27
06/28
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

Recruiting
2
450
Europe, Canada, Japan, US, RoW
LY3848575, Placebo
Eli Lilly and Company
Neuropathic Pain, Distal Sensory Polyneuropathy
06/26
09/26
Nedd, Kester
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

Recruiting
2
450
Europe, Canada, Japan, US, RoW
LY3848575, Placebo
Eli Lilly and Company
Neuropathic Pain, Distal Sensory Polyneuropathy
06/26
09/26

Download Options